Integrated sample prep Potential to cross-sell expanded sample preparation capabilities following recent acquisitions of Two Square Science and BEE International, enabling a broader toolkit for formulation support and accelerated drug development.

In vitro focus Strong emphasis on in vitro analytical solutions for dissolution, phys chem analysis, and in vitro predicted performance presents cross-selling opportunities for instrument upgrades, maintenance contracts, and contract research offerings.

Subcutaneous testing Recent SCISSOR N3 launch signals demand for robust in vitro models of subcutaneous formulations; target pharma and biotech teams seeking predictive release data and automation-ready testing platforms.

End-to-end services Hybrid model combining instruments, lab services, and maintenance creates recurring revenue potential through service contracts, screens, assays, and data analysis engagements for drug development programs.

Growth and capacity Mid-sized company with broad revenue range and recent acquisitions indicates capacity to scale partnerships, offer co-development opportunities, and pursue larger collaboration or contract research arrangements with pharma players.